title: Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats.
abstract: The work shows the effects of caffeine after the intrastriatal injection of 6-OHDA in rats, considered as a model of Parkinson disease (PD). Two weeks after the 6-OHDA lesion, rats exhibit a characteristic rotation behavior as a response to the apomorphine challenge. Our results showed significant increases in the number of apomorphine-induced rotations in 6-OHDA-lesioned rats, as compared to sham-operated animals. A partial recovery was observed in 6-OHDA-lesioned rats, after caffeine (10 and 20 mg/kg, i.p., daily for 14 days) treatment. The stereotaxic injection of 6-OHDA produced loss of striatal neurons, as indicated by the decrease in monoamines levels, in the ipsilateral side (75-85%) when compared to the contralateral side. Significant decreases in noradrenaline levels were seen in the ipsilateral side of 6-OHDA group (62%), and this effect was not significantly reversed in caffeine-treated groups. While significant decreases in dopamine levels were seen in the ipsilateral side of 6-OHDA group (78%), in the caffeine-treated group (10 and 20 mg/kg, i.p.) the decreases were only 53 and 18%, indicating significant recoveries. In conclusion, our data demonstrated beneficial effects of caffeine in this model of PD, suggesting the potential use of A2A antagonists as a novel treatment for this neurodegenerative disease.
authors.affiliation: Federal University of Ceará, Brazil. lissiana_m@yahoo.com.br
authors.forename: Lissiana Magna Vasconcelos
authors.initials: LM
authors.lastname: Aguiar
authors.forename: Hélio V
authors.initials: HV
authors.lastname: Nobre
authors.forename: Danielle S
authors.initials: DS
authors.lastname: Macêdo
authors.forename: Aline A
authors.initials: AA
authors.lastname: Oliveira
authors.forename: Rivelilson M
authors.initials: RM
authors.lastname: Freitas
authors.forename: Silvânia M
authors.initials: SM
authors.lastname: Vasconcelos
authors.forename: Geanne M A
authors.initials: GM
authors.lastname: Cunha
authors.forename: Francisca Cléa F
authors.initials: FC
authors.lastname: Sousa
authors.forename: Glauce Socorro B
authors.initials: GS
authors.lastname: Viana
mesh_terms: D000818:Animals; D001058:Apomorphine / Q000378:metabolism; D001921:Brain / Q000187:drug effects / Q000473:pathology; D001927:Brain Diseases / Q000188:drug therapy; D002110:Caffeine / Q000378:metabolism / Q000494:pharmacology*; D004195:Disease Models, Animal; D015259:Dopamine Agents / Q000378:metabolism; D008297:Male; D009474:Neurons / Q000187:drug effects; D018696:Neuroprotective Agents / Q000494:pharmacology*; D016627:Oxidopamine / Q000378:metabolism*; D010300:Parkinson Disease / Q000188:drug therapy; D051381:Rats; D017208:Rats, Wistar
chemical_list: D015259:Dopamine Agents; D018696:Neuroprotective Agents; D002110:Caffeine; D016627:Oxidopamine; D001058:Apomorphine